Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2021-10-01
2022-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optical Coherence Tomography Angiography (OCT-A) and Central Serous Chorioretinopathy (CSC)
NCT03950089
Imaging of Retinochoroidal Vasculature in Patients Being Assessed for Cardiovascular Disease
NCT05082402
OCTA Insights in CNVM, Morphological Characteristics and Correlation With Structural OCT.
NCT05055973
Fundus Optical coheRence Tomography Angiography Evaluation for Small-vessel Health in Cerebral Small Vessel Disease
NCT06431711
Retinal Vessel Leakage in Cerebral Small Vessel Disease
NCT06416371
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Vascular risk factors that are commonly found in large vessel disease have shown to contribute to CSVD, as well, including hypertension, diabetes mellitus, smoking and dyslipidemia.Also old age is considered to be a risk factor as the prevelance of CSVD increases with age affecting nearly 5 % of people aged 50 years and almost 100% in those older than 90 years .
Cerebral amyloid angiopathy is one of the suggested underlying pathologies in some cases of CSVD.
Clinically, CSVD accounts for 25% of ischemic strokes and 50% of dementias . It may present as acute events (focal neurological deficit ) known as lacunar syndrome or chronic events as mild cognitive dysfunction, dementia, mood disorders, gait disturbance, sleep disorder and urinary incontinence. Also, it may be a symptomatic.
Although CSVD is a common reason for strokes and vascular dementia, pathogenesis is still poorly understood . It is suggested that the endothelial dysfunction in cerebral microvessels may be a key problem. Endothelial failure leads to increased permeability and increased leakage into the vessel wall and the surrounding tissue , damaging of the vessel wall , inflammation, demyelination, glial scar formation , thickening and stiffness of vessels leading to failure of autoregulation, narrowing of the lumen and occlusion , causing featured focal ischemic lesions in the brain parenchyma.
Neuroimaging markers seen on MRI are classified into: Recent small subcortical infarct (DWI), Lacune of presumed vascular origin (FLAIR), White matter hyperintensity of presumed vascular origin (FLAIR), Perivascular space (T1 , T2), cerebral microbleed (T2\*-weighted GRE/SWI).
The changes in brain microvasculature are difficult to be visualized in vivo . Because of similarities between brain and retina in anatomy , embryology and physiology , investigating the retinal vessels network may reflect the brain condition.
Optical coherence tomography angiography ( OCTA ) is a novel, real-time and noninvasive technique to detect retinal and choroidal blood flow in vivo.
The retinal capillary network is arranged anatomically into several layers as following ; 3 macular plexuses, 4 plexuses in peripapillary region and one capillary layer in midequatorial and anterior zones where the retina is thinner. OCTA devices are based on (en face) approach to get information of the superficial and deep plexuses. 4 en face zones are detected ; superfacial plexus in ganglion cell layer, deep plexus, photoreceptors(outer retina) and choroiocapillaries. For each en face zone , the indices of perfusion could be reached.
OCTA has a big advantage over classic methods as retinal microvasculature are segmented into layers and can be visualized and quantified more accurately . It is a safe and rapid technique giving a vascular map of retinal blood flow without using intravenous dye.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case group
40 patients according to inclusion criteria .
Optical coherence tomography angiography
OCT-A detects the motion of blood using intrinsic signals to capture the location of blood vessels. Despite its insensitivity to leakage and the relatively small field of view, the development of OCT-A has the potential to improve our knowledge of the physiology and pathophysiology of the eye.
MRI as a stroke protocol, including T1 and T2 weighted images, diffusion weighted images (DWI), fluid attenuated inversion recovery (FLAIR), magnetic resonance angiography (MRA), and gradient recalled echo (GRE) T2\* weighted images, using a machine 1.5 tesla General Electric machine .
Control group
20 normal people with no history of previous brain insult and with free neurological examination .
Optical coherence tomography angiography
OCT-A detects the motion of blood using intrinsic signals to capture the location of blood vessels. Despite its insensitivity to leakage and the relatively small field of view, the development of OCT-A has the potential to improve our knowledge of the physiology and pathophysiology of the eye.
MRI as a stroke protocol, including T1 and T2 weighted images, diffusion weighted images (DWI), fluid attenuated inversion recovery (FLAIR), magnetic resonance angiography (MRA), and gradient recalled echo (GRE) T2\* weighted images, using a machine 1.5 tesla General Electric machine .
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Optical coherence tomography angiography
OCT-A detects the motion of blood using intrinsic signals to capture the location of blood vessels. Despite its insensitivity to leakage and the relatively small field of view, the development of OCT-A has the potential to improve our knowledge of the physiology and pathophysiology of the eye.
MRI as a stroke protocol, including T1 and T2 weighted images, diffusion weighted images (DWI), fluid attenuated inversion recovery (FLAIR), magnetic resonance angiography (MRA), and gradient recalled echo (GRE) T2\* weighted images, using a machine 1.5 tesla General Electric machine .
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. must be at age of 50 or more.
Exclusion Criteria
2. Patients with any type of cerebral haemorrhage .
3. Diabetic patients .
4. concurrent retinal diseases as epiretinal memberane and macular degeneration.
5. Past history of retinal operation or ocular surgery except for cataract surgery.
6. An history of glaucoma or optic neuropathy.
7. hematological diseases and coagulopathies.
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Cannistraro RJ, Badi M, Eidelman BH, Dickson DW, Middlebrooks EH, Meschia JF. CNS small vessel disease: A clinical review. Neurology. 2019 Jun 11;92(24):1146-1156. doi: 10.1212/WNL.0000000000007654. Epub 2019 May 29.
Chen X, Wang J, Shan Y, Cai W, Liu S, Hu M, Liao S, Huang X, Zhang B, Wang Y, Lu Z. Cerebral small vessel disease: neuroimaging markers and clinical implication. J Neurol. 2019 Oct;266(10):2347-2362. doi: 10.1007/s00415-018-9077-3. Epub 2018 Oct 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
930107130
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.